Philips names Stryker’s Charlotte Hanneman as CFO
Abhijit Bhattacharya, who took over as CFO in 2015 and has spent 37 years with the company, will step down in October.
Philips names Stryker’s Charlotte Hanneman as CFO Read More »
Uncategorized
Insulet sizes up competition as Tandem, Medtronic plan new insulin patch-pumps
Insulet CEO Jim Hollingshead said the company is “very confident” in its competitive position as rivals develop their own patch pumps.
Insulet sizes up competition as Tandem, Medtronic plan new insulin patch-pumps Read More »
Integra Lifesciences CEO Jan De Witte to retire
The company is working to restart a factory in Boston after problems at the plant led to a sweeping recall in 2023. De Witte will stay with Integra until it finds a successor.
BlossomHill Therapeutics Closes $100 Million Series B Financing
BlossomHill Therapeutics, Inc. today announced the closing of a $100 million Series B financing round.
BlossomHill Therapeutics Closes $100 Million Series B Financing Read More »
Tenet to sell two California hospitals to Adventist for $550M
The latest divestiture comes as the Dallas-based for-profit has sold other hospitals while it reduces its debt load.
Tenet to sell two California hospitals to Adventist for $550M Read More »
FORE Biotherapeutics Names William R. Hinshaw as Chief Executive Officer
FORE Biotherapeutics today announced the appointment of William R. Hinshaw as the Chief Executive Officer and Director of the Board.
FORE Biotherapeutics Names William R. Hinshaw as Chief Executive Officer Read More »
Northwell Health, Nuvance Health to merge
The proposed deal would create a 28-hospital system in New York and Connecticut.
Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults
Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO ® for RSV in Older Adults.
Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the fourth quarter and full year ended December 31, 2023.
Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
Janux Therapeutics, Inc. announced the pricing of an underwritten public offering of 4,440,851 shares of its common stock at a public offering price of $46.50 per share and pre-funded warrants to purchase 1,935,483 shares of common stock at a price of $46.499 per pre-funded warrant, which represents the per share price for the common stock